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Table 1. Expression of mdrl and mdr3 multidrug- 
resistance genes in hairy cell leukemia 
Expression (units) 
Patient no. mdrl mdr3 
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CHEMOTHERAPY REMAINS an important treatment modality for 
cytoreduction of leukaemias. However, drug effectiveness can 
be greatly reduced as a result of the occurrence of cellular drug 
resistance. Some of the most widely used cytotoxic drugs (i.e. 
anthracyclines, vinca alkaloids, podophyllotoxins) have in vitro 
been linked to the so-called multidrug-resistance (MDR) pheno- 
type. MDR cells are characterised by a lowered intracellular 
drug accumulation that is due to activity of an energy dependent 
unidirectional drug efflux pump with broad substrate specificity 
[l]. This drug pump is composed of a transmembrane glyco- 
protein (P-glycoprotein) which is encoded by the human mdrl 
gene [2]. In man, a second highly homologous gene has been 
found, which is named alternatively mdr2 [3], or m&3 [4]. 
The mdrl gene has been reported to be expressed in human 
cancers, including a variety of haematological malignancies 
[ 5-71. Expression of the mdr3 gene is mainly found in normal 
liver [4]. Recently, we found mdr3 expression in leukaemia 
samples. These studies suggested that mdr3 expression is exclus- 
ively found in B-cell type leukaemias [7, 81. In the present 
study, we further investigated the expression of both m&l and 
mdr3 in the peripheral blood or spleen cells from adult patients 
with B-hairy cell leukaemia (HCL). A highly specific and 
sensitive RNase protection assay was used, with a lower limit of 
detection of approximately 0.2 units [7]. Levels of m&l and 
mdr3 expression found in peripheral blood or spleen cells from 
8 patients with HCL are given in Table 1. Expression of both 
mdrl and mdr3 was detected in all 8 samples studied. In general, 
mdr3 levels were higher than mdrl levels. For the 8 samples 
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1 0.3 15 
2 0.5 50 
3 1 9 
4 2 10 
5 4 3 
6 9 20 
7 11 50 
8 35 15 
Expression levels were determined using an RNase 
protection assay [7]. The levels were quantitated rela- 
tive to the expression of KB-8-5 MDR cell line, as 
proposed in [S]. 
studied, the mean level of expression of m&l and mdr3 were 
8 U and 22 U, respectively. The tirl expression levels varied 
between 0.3 and 35 units (U); the m&3 levels between 3 and 
50 U, with no apparent correlation between the two. 
Treatment of HCL is usually started with splenectomy, 
followed by prolonged interferon-a, and/or deoxycoformycin 
administration. Prolonged, control of disease is possible follow- 
ing this scheme [9, lo]. Intensive chemotherapy with cytotoxic 
drugs, such as anthracyclines, is considered as third line therapy 
[lo]. The results presented in this study show low to intermediate 
expression of the mdrl gene (related to the classical MDR 
phenotype) and moderate to high expression of the mdr3 gene 
(presumably also involved in drug resistance [7, 81) in all studied 
HCL samples. Therefore, it may be anticipated that results of 
chemotherapy with MDR-related drugs in HCL patients will 
be disappointing due to the frequent occurrence of the MDR 
phenotype. Combination of MDR-related drugs with MDR 
reversal agents (such as verapamil, cyclosporin and many others) 
are now evaluated in clinical trials for improved treatment of 
acute myelocytic leukaemia and multiple myeloma [ 11, 121. In 
these malignancies, elevated levels of mdrl expression have been 
found, and the acquisition of clinical drug resistance is frequently 
encountered [6, 7, 111. When proven successful, such a combi- 
nation therapy might be a good alternative for third line therapy 
of hairy cell leukaemia. 
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Lymph-node Irradiation in Operable 
Breast Cancer and Statistical Power 
Rodrigo Arriagada and Lars-Erik Rutqvist 
PROFESSOR Veronesi et al. (vol. 26, pp. 668-670) recently 
updated results of the Milan breast conservation trial. Patients 
with positive axillary nodes were included in a second randomis- 
ation during the first 3 years of the trial to evaluate the effect of 
adjuvant radiotherapy to supraclavicular and internal mammary 
nodes. Results did not show improved survival of treated 
compared with non-treated patients. Veronesi et al. did not state 
the number of randomised patients. However, if we assume that 
accrual was constant during the period of patients’ entry (88 per 
year) and that all node positive patients were included (26%), 
we have estimated that approximately 70 patients may have 
been studied. If lymph-node irradiation can improve long-term 
survival by 10% (similar to other adjuvant treatments) the 
number of patients needed to test this hypothesis is more than 
700 (IX risk = 0.05, p risk = 0.10). A trial of this size would 
have a statistical power of 90%-i.e. only a 1:lO chance of 
concluding that there is no difference when actually there is. 
The second randomisation of the Milan trial has a statistical 
power of only lO%-i.e. a 9:lO chance of concluding that there 
is no difference when really there is. Therefore, the trial is too 
small to give a definite answer to the question raised. 
There is retrospective [l] and prospective [2, 31 evidence that 
megavoltage lymph-node irradiation with adequate doses can 
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decrease the distant metastasis rate, and consequently may have 
an effect on overall survival in node positive patients. Because 
of low statistical power, the Milan trial does not add much 
knowledge to this issue. Unfortunately, a quick reading of the 
Milan paper might result in conclusions that are not supported 
by reported data [4]. 
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Reply by U. Veronesi et al. 
THE TRIAL was designed to compare Halsted mastectomy and 
quadrantectomy plus radiotherapy (QUART) in terms of 
relapse-free and overall survival. 
In our analysis we focused on overall survival, regardless of 
adjuvant therapies. 4 subgroups have been identified and the 
log rank test has been carried out accordingly (Table 1). 
We agree with Dr Arriagada and Dr Rutqvist that in our 
paper the sentence concerning radiotherapy might be confusing. 
However, 16/35 unfavourable events have been observed in 
subset B radiotherapy and 20/33 in subset C adjuvant radio- 
therapy; these findings are at the basis of our statement to which, 
however, no statistical relevance was attributed in the paper. 
Table 1. 
A B C D 
N- N+ N-t Nt 
no adjwvant +adjuvant + adjuvant CT 
regional RT 
Halsted 263 15 15 56 
QUART 257 20 18 57 
Total 520 35 33 113 
N- = node negative; N+ = node positive; RT = radiotherapy; 
CT = chemotherapy. 
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